Variants and chemically-modified variants of phenylalanine...

Details Variants and chemically-modified variants of phenylalanine... Variants and chemically-modified variants of phenylalanine...

2005-09-19

2009-06-30

Carlson, Karen Cochrane (Department: 1656)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Lyase

Reexamination Certificate

active

07553653

ABSTRACT:
The present invention pertains to the use of the protein phenylalanine ammonia-lyase, as well as the biologically-active derivatives of the said protein for preventing or treating diseases associated with a phenylalanine imbalance in a human or animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating a phenylalanine imbalance in vivo. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting more therapeutically-effective variants of said protein as well as to the selected variants themselves.

REFERENCES:
patent: 4562151 (1985-12-01), Kishore
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5753487 (1998-05-01), Eigtved et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5981239 (1999-11-01), Liu
patent: 6451986 (2002-09-01), Pettit
patent: 6461849 (2002-10-01), Olsen et al.
patent: 6586398 (2003-07-01), Kinstler et al.
patent: 6686164 (2004-02-01), Olsen et al.
patent: 2002/0052038 (2002-05-01), Roberts et al.
patent: 2002/0102712 (2002-08-01), Yoshida et al.
patent: 2003/0082238 (2003-05-01), Babich et al.
patent: WO 90/12874 (1990-11-01), None
patent: WO 03/072743 (2003-09-01), None
patent: WO 2004/044169 (2004-05-01), None
Langer et al. Identification of Essential Amino Acids in Phenylalanine Ammonia-Lyase by Site-Directed Mutagenesis. Biochemistry, 1997. vol. 36, pp. 10867-10871.
Christiansen et al. The Role of the MoFe protein alpha-125-Phe and beta-125-Phe Residues in Azotobacter vinelandii MoFe-Fe protein Interaction. Journal of Inorganic Biochemistry. 2000, vol. 80, pp. 195-204.
Sorlie et al. Mechanistic Features and Structure of the Nitrogenase alpha-Gin-195 MoFe protein. Biochemistry. 2001, vol. 40, pp. 1540-1549.
Abell et al., “An In Vivo Evaluation of the Chemotherapeutic Potency of Phenylalanine Ammonia-Lyase,” Cancer Research, Oct. 1973, pp. 2529-2532, vol. 33.
Abell et al., “Phenylalanine Ammonia-Lyase from the Yeast Rhodotorula Glutinis,” Methods in Enzymology, 1987, pp. 242-253, vol. 142.
Abrams et al., “Rational Antigen Modification as a Strategy to Upregulate or Downregulate Antigen Recognition,” Current Opinion Immunology, 2000, pp. 85-91, vol. 12.
Alunni et al., “Mechanisms of Inhibition of Phenlalanine Ammonia-Lyase by Phenol Inhibitors and Phenol/Glycine Synergistic Inhibitors,” Archives of Biochemistry and Biophysics, 2003, pp. 170-175, vol. 412.
Ambrus et al., “Depletion of Phenylalanine in the Blood of Phenylketonuric Patients Using a PAL-Enzyme Reactor, an In Vitro Study,” Research Communications in Chemical Pathology and Phamacology, Jun. 1982, pp. 105-111, vol. 37, No. 1.
Ambrus et al., “Extracorporeal Enzyme Reactors for Depletion of Phenylalanine in Phenylketonuria,” Annals of Internal Medicine, 1987, pp. 531-537, vol. 106.
Ambrus et al., “In Vivo Safety of Hollow Fiber Enzyme-Reactors with Immobilized Phenylalanine Ammonia-Lyase in a Large Animal Model for Phenylketonuria,” The Journal of Pharmacology and Experimental Therapeutics, 1983, pp. 598-602, vol. 224, No. 3.
Ambrus et al., “Phenylalanine Depletion for the Management of Phenylketonuria: Use of Enzyme Reactors with Immobilized Enzymes,” Science, Sep. 1978, pp. 837-839, vol. 201.
Bourget et al., “Artificial Cell-Microencapsulated Phenylalanine Ammonia-Lyase,” Applied Biochemistry and Biotechnology, 1984, pp. 57-59, vol. 10.
Bourget et al., “Phenylalanine Ammonia-Lyase Immobilized in Semipermeable Microcapsules for Enzyme Replacement in Phenylketonuria,” Federation of European Biochemical Societies Letters, Jan. 1985, pp. 5-8, vol. 180, No. 1.
Bourget et al., “Phenylalanine Ammonica-Lyase Immobilized in Microcapsules for the Depletion of Phenylalanine in Plasma in Phenylketonuric Rat Model,” Biochimica et Biophysica Acta, 1986, pp. 432-438, vol. 883.
Brannigan et al., “Protein Engineering 20 Years On,” Nature Reviews, Molecular Cell Biology, Dec. 2002, pp. 964-970, vol. 3.
Chang et al., “A New Theory of Enterorecirculation of Amino Acids and Its Use for Depleting Unwanted Amino Acids Using Oral Enzyme-Artificial Cells, as in Removing Phenylalanine in Phenylketonuria,” Art. Cells Blood Subs. and Immob. Biotech., 1995, pp. 1-21, vol. 23, No. 1.
Chang et al., “Procedures for Microencapsulation of Enzymes, Cells and Genetically Engineered Microorganisms,” Molecular Biotechnology, 2001, pp. 249-260, vol. 17.
Chen et al., “Tuning the Activity of an Enzyme for Unusual Environments: Sequential Random Mutagenesis of Subtilism E for Catalysis in Dimethylformamide,” Proc. Natl. Acad. Sci. U.S.A., Jun. 1993, pp. 5816-5622, vol. 90.
Chirino et al., “Minimizing the Immunogenicity of Protein Therapeutics,” Drug Discovery Today, Jan. 2004, pp. 82-90, vol. 9, No. 2.
Delgado et al., “The Uses and Properties of PEG-Linked Proteins,” Critical Reviews in Therapeutic Drug Carrier Systems, 1992, pp. 249-304, vol. 9, No. 3-4.
Egrie et al., “Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP),” British Journal of Cancer, 2001, pp. 3-10, vol. 84, (Supplement 1).
Fritz et al., “Phenylalanine Ammonia-Lyase,” The Journal of Biological Chemistry, Aug. 10, 1976, pp. 4646-4650, vol. 251, No. 15.
Gilbert et al., “The Effect of Proteinases on Phenylalanine Ammonia-Lyase from the Yeast Rhodotorula Glutinis,” Biochem. J., 1981, pp. 715-723, vol. 199.
Gilbert et al., “Protection of Phenylalanine Ammonia-Lyase from Proteolytic Attack,” Biochemical and Biophysical Research Communications, Sep. 16, 1985, pp. 557-563, vol. 131, No. 2.
Goodson et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at Its Glycosylation Site,” Biotechnology, Apr. 1990, pp. 343-346, vol. 8.
Graham, “Pegaspargase: A Review of Clinical Studies,” Advanced Drug Delivery Reviews, 2003, pp. 1293-1302, vol. 55.
Greenwald et al., “Effective Drug Delivery by PEGylated Drug Conjugates,” Advanced Drug Delivery Reviews, 2003, pp. 217-250, vol. 55.
Harris et al., “Effect of Pegylation on Pharmaceuticals,” Nature Reviews, Drug Discovery, Mar. 2003, pp. 214-221, vol. 2.
Hedstrom et al., “Converting Trypsin to Chymotrypsin: The Role of Surface Loops,” Science, Mar. 6, 1992, pp. 1249-1253, vol. 255, No. 5049.
Hemeling et al., “Structure-Immunogenicity Relationships of Therapeutic Proteins,” Pharmaceutical Research, Jun. 2004, pp. 897-903, vol. 21, No. 6.
Hershfield, Enzyme Replacement Therapy of Adenosine Deaminase Deficiency with Polyethylene Glycol-Modified Adenosine Deaminase (PEG-ADA), Immunodeficiency, 1993, pp. 93-97, vol. 4.
Hershfield et al., “Use of Site-Directed Mutagenesis to Enhance the Epitope-Shielding Effect of Covalent Modification of Proteins with Polyethylene Glycol,” Proc. Natl. Acad. Sci. USA, Aug. 1991, pp. 7185-7189, vol. 88.
Hopfner et al., “New Enzyme Lineages by Subdomain Shuffling,” Proc. Natl. Acad. Sci., USA, Aug. 1998, pp. 9813-9818, vol. 95.
Hoskins et al., “Enzymatic Control of Phenylalanine Intake in Phenylketonuria,” The Lancet, Feb. 23, 1980, pp. 392-394.
Hoskins et al., “The Metabolism of Cinnamic Acid by Healthy and Phenylketonuric Adults: a Kinetic Study,” Biomedical Mass Spectrometry, 1984, pp. 296-300, vol. 11, No. 6.
Hoskins et al., “Phenylalanine Ammonia Lyase in the Management of Phenylketonuria: The Relationship Between Ingested Cinnamate and Urinary Hippurate in Humans,” Research Communications in Chemical Pathology and Pharmacology, Feb. 1982, pp. 275-282, vol. 35, No. 5.
Kalghatgi et al., &

Affiliated with

Also associated with

Rating

Variants and chemically-modified variants of phenylalanine... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Variants and chemically-modified variants of phenylalanine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants and chemically-modified variants of phenylalanine... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4103805